Upjohn President Hoff resigns
Executive Summary
Lawrence Hoff, 60, announces resignation, effective Jan. 1. Hoff's departure is part of the transition plan unveiled in November with the establishment of a five-man office of the chairman. That management group was headed by Chairman Theodore Cooper and included three newly appointed exec VPs: ex-FDA Commissioner Mark Novitch; the head of Upjohn's pharmaceutical business, Ley Smith; and the head of the consumer and chemical products, William Parfet. As scion of the Parfet family, which controls approximately 7% of Upjohn common stock, William Parfet's progress through the executive ranks is being watched closely. Cooper will assume Hoff's title as president as well as hold the chairmanship after Jan. 1. Hoff is retiring after a 40-year career spent entirely at Upjohn.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.